Biosynexus Incorporated

Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in the setting of the neonatal intensive care unit (NICU). The company has two additional product candidates: lysostaphin for the treatment of life threatening staphylococcal infections and nisin a topical cream for treating serious skin infections. Biosynexus' mission is bringing products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants.